NeuroSense Therapeutics Ltd.

NRSN | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.36

-$0.63 (-31.66%)

Nov 2, 2026, 2:25 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Pro Subscription

Upgrade now for unlimited access to all data, tools and no ads.

Upgrade now ➞

Related Stocks

Company	Yield
CLGN CollPlant Biotechnologies	N/A
CVKD Cadrenal Therapeutics Common Stock	N/A
NERV Minerva Neurosciences	N/A
NRXS NeurAxis	N/A
RLYB Rallybio	N/A
TAOX TAO Synergies	N/A
XCUR Exicure	N/A

Dividend Rankings ➞

Recent News

2 months ago / prnewswire.com
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
2 months ago / prnewswire.com
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
3 months ago / prnewswire.com
NeuroSense Issues CEO Letter to Shareholders
3 months ago / gurufocus.com
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
3 months ago / prnewswire.com
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
4 months ago / prnewswire.com
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
4 months ago / gurufocus.com
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
4 months ago / prnewswire.com
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease